UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, exercised 9,500 options and sold about 9,490 shares of common stock on July 8, 2026 under a 10b5‑1 plan for roughly $5.25 million in gross proceeds.

On July 8, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring 9,500 shares of common stock, and on the same day sold an aggregate 9,490 shares of common stock in a series of open‑market transactions at prices ranging from approximately $548.62 to $560.79 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. The gross proceeds from the sales totaled roughly $5.25 million, while the option exercise cost was about $1.29 million, resulting in a net monetization of approximately $3.95 million before taxes and fees. Following these transactions, Rothblatt directly held 39,718 shares of common stock, in addition to substantial indirect holdings through family trusts and her spouse: 166 shares held by her spouse, 324,443 shares held by one family trust, 249,108 shares by another family trust, 45,596 shares by a further family trust, 8,902 shares by another trust, and 349,192 shares held indirectly via a trust in stock options (all expiring March 15, 2027), reflecting significant continuing economic exposure to the company despite the programmed sales.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000094

Alert Tier

7